Fiasp - Another Insulin Aspart Formulation for Diabetes
Date: January 1, 2018
Issue #:
1537Summary:
The FDA has approvedFiasp (Novo Nordisk), a new
formulation of insulin aspart, to improve glycemic
control in adults with diabetes.Fiasp is described by
the manufacturer as faster-acting than conventional
insulin aspart(Novolog).
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Source Type: research